Recent advances in the treatment of advanced or recurrent endometrial cancer

References

• Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. FIGO 6th annual report on the results of treatment in gynecological cancer. Int. J. Gynaecol. Obstet.95(Suppl. 1), S105–S143 (2006).
   PubMed Web of Science ®Google Scholar
• Kitchener H, Swart AM, Qian Q, Amos C, Parmar MK; ASTEC Study Group, Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study Lancet373(9658), 125–136 (2009).
   PubMed Web of Science ®Google Scholar
• Creasman WT, Odicino F, Maisonneuve P et al. Carcinoma of the corpus uteri. J. Epidemiol. Biostat.6(1), 47–86 (2001).
   PubMedGoogle Scholar
• Matias-Guiu X, Catasus L, Bussaglia E et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum. Pathol.32(6), 569–577 (2001).
   PubMed Web of Science ®Google Scholar
• Bremond A, Bataillard A, Thomas L et al. Cancer of the endometrium. Br. J. Cancer84(Suppl. 2), 31–36 (2001).
   PubMedGoogle Scholar
• Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol. Oncol.78(2), 85–91 (2000).
   PubMed Web of Science ®Google Scholar
• Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol. Oncol.67(1), 56–60 (1997).
   PubMed Web of Science ®Google Scholar
• Goff BA, Goodman A, Muntz HG, Fuller AF Jr, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol. Oncol.52(2), 237–240 (1994).
   PubMed Web of Science ®Google Scholar
• Memarzadeh S, Holschneider CH, Bristow RE et al. FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int. J. Gynecol. Cancer12(5), 454–458 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol.107(2), 190–193 (2007).
   PubMed Web of Science ®Google Scholar
• Pliskow S, Penalver M, Averette HE. Stage III and stage IV endometrial carcinoma: a review of 41 cases. Gynecol. Oncol.38(2), 210–215 (1990).
   PubMed Web of Science ®Google Scholar
• Holland CM. The role of radical surgery in carcinoma of the endometrium. Clin. Oncol. (R. Coll. Radiol.)20(6), 448–456 (2008).
   PubMed Web of Science ®Google Scholar
• Awtrey CS, Cadungog MG, Leitao MM et al. Surgical resection of recurrent endometrial carcinoma. Gynecol. Oncol.102(3), 480–488 (2006).
   PubMed Web of Science ®Google Scholar
• Bristow RE, Santillan A, Zahurak ML, Gardner GJ, Giuntoli RL 2nd, Armstrong DK. Salvage cytoreductive surgery for recurrent endometrial cancer. Gynecol. Oncol.103(1), 281–287 (2006).
   PubMed Web of Science ®Google Scholar
• Campagnutta E, Giorda G, De Piero G et al. Surgical treatment of recurrent endometrial carcinoma. Cancer100(1), 89–96 (2004).
   PubMed Web of Science ®Google Scholar
• Scarabelli C, Campagnutta E, Giorda G et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol. Oncol.70(1), 90–93 (1998).
   PubMed Web of Science ®Google Scholar
• Barakat RR, Goldman NA, Patel DA, Venkatraman ES, Curtin JP. Pelvic exenteration for recurrent endometrial cancer. Gynecol. Oncol.75(1), 99–102 (1999).
   PubMed Web of Science ®Google Scholar
• Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol. Oncol.60(2), 288–291 (1996).
   PubMed Web of Science ®Google Scholar
• Kong A, Johnson N, Cornes P et al. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst. Rev. (2), CD003916 (2007).
   Google Scholar
• Greven KM, Corn BW, Case D, Purser P, Lanciano RM. Which prognostic factors influence the outcome of patients with surgically staged endometrial cancer treated with adjuvant radiation? Int. J. Radiat. Oncol. Biol. Phys.39(2), 413–418 (1997).
   PubMed Web of Science ®Google Scholar
• Hetu V, Petignat P, Wu Y et al. Positive adnexal or uterine serosal involvement in stage IIIC endometrial cancer is an adverse factor for recurrence. Gynecol. Obstet. Invest.67(3), 173–177 (2009).
   PubMed Web of Science ®Google Scholar
• Mariani A, Dowdy SC, Cliby WA et al. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol. Oncol.101(2), 200–208 (2006).
   PubMed Web of Science ®Google Scholar
• Fakiris AJ, Randall ME. Endometrial carcinoma: the current role of adjuvant radiation. J. Obstet. Gynaecol.29(2), 81–89 (2009).
   PubMedGoogle Scholar
• Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br. J. Cancer95(3), 266–271 (2006).
   PubMed Web of Science ®Google Scholar
• Randall ME, Filiaci VL, Muss H et al. Randomized Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol.24(1), 36–44 (2006).
   PubMed Web of Science ®Google Scholar
• Susumu N, Sagae S, Udagawa Y et al. Randomized Phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol. Oncol.108(1), 226–233 (2008).
   PubMed Web of Science ®Google Scholar
• Creutzberg CL, van Putten WL, Koper PC et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol. Oncol.89(2), 201–209 (2003).
   PubMed Web of Science ®Google Scholar
• Hoekstra CJ, Koper PC, van Putten WL. Recurrent endometrial adenocarcinoma after surgery alone: prognostic factors and treatment. Radiother. Oncol.27(2), 164–166 (1993).
   PubMed Web of Science ®Google Scholar
• Sears JD, Greven KM, Hoen HM, Randall ME. Prognostic factors and treatment outcome for patients with locally recurrent endometrial cancer. Cancer74(4), 1303–1308 (1994).
   PubMed Web of Science ®Google Scholar
• Wylie J, Irwin C, Pintilie M et al. Results of radical radiotherapy for recurrent endometrial cancer. Gynecol. Oncol.77(1), 66–72 (2000).
   PubMed Web of Science ®Google Scholar
• Kauppila A. Progestin therapy of endometrial, breast and ovarian carcinoma. A review of clinical observations. Acta Obstet. Gynecol. Scand.63(5), 441–450 (1984).
   PubMed Web of Science ®Google Scholar
• Lentz SS, Brady MF, Major FJ, Reid GC, Soper JT. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol.14(2), 357–361 (1996).
   PubMed Web of Science ®Google Scholar
• Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Medroxyprogesterone acetate (Depo-Provera) vs hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer45(2), 268–272 (1980).
   PubMed Web of Science ®Google Scholar
• Podratz KC, O’Brien PC, Malkasian GD Jr, Decker DG, Jefferies JA, Edmonson JH. Effects of progestational agents in treatment of endometrial carcinoma. Obstet. Gynecol.66(1), 106–110 (1985).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Alvarez RD et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the Gynecologic Oncology Group. J. Clin. Oncol.17(6), 1736–1744 (1999).
   PubMed Web of Science ®Google Scholar
• Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int. J. Gynecol. Cancer17(5), 964–978 (2007).
   PubMed Web of Science ®Google Scholar
• Fiorica JV, Brunetto VL, Hanjani P, Lentz SS, Mannel R, Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.92(1), 10–14 (2004).
   PubMed Web of Science ®Google Scholar
• Whitney CW, Brunetto VL, Zaino RJ et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.92(1), 4–9 (2004).
   PubMed Web of Science ®Google Scholar
• Burke TW, Walker CL. Arzoxifene as therapy for endometrial cancer. Gynecol. Oncol.90(2 Pt 2), S40–S46 (2003).
   Google Scholar
• McMeekin DS, Gordon A, Fowler J et al. A Phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol.90(1), 64–69 (2003).
   PubMed Web of Science ®Google Scholar
• Rose PG, Brunetto VL, VanLe L, Bell J, Walker JL, Lee RB. A Phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol.78(2), 212–216 (2000).
   PubMed Web of Science ®Google Scholar
• Ma BB, Oza A, Eisenhauer E et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers – a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer14(4), 650–658 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J. Clin. Oncol.25(20), 2983–2990 (2007).
   PubMed Web of Science ®Google Scholar
• Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J. Clin. Oncol.20(9), 2360–2364 (2002).
   PubMed Web of Science ®Google Scholar
• Escobar PF, Markman M, Zanotti K, Webster K, Belinson J. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J. Cancer Res. Clin. Oncol.129(11), 651–654 (2003).
   PubMed Web of Science ®Google Scholar
• Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A Phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol. Oncol.63(1), 25–27 (1996).
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Genazzani AR. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit. Rev. Oncol. Hematol.58(3), 242–256 (2006).
   PubMed Web of Science ®Google Scholar
• Aapro MS, van Wijk FH, Bolis G et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC Gynaecological Cancer Group. Ann. Oncol.14(3), 441–448 (2003).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Brunetto VL, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol.22(11), 2159–2166 (2004).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann. Oncol.15(8), 1173–1178 (2004).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol.12(7), 1408–1414 (1994).
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J. Clin. Oncol.22(19), 3902–3908 (2004).
   PubMed Web of Science ®Google Scholar
• Homesley HD, Filiaci V, Gibbons SK et al. A randomized Phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol. Oncol.112(3), 543–552 (2009).
   PubMed Web of Science ®Google Scholar
• Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann. Oncol.18(3), 409–420 (2007).
   PubMed Web of Science ®Google Scholar
• Sorbe B, Andersson H, Boman K, Rosenberg P, Kalling M. Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxel-long-term follow-up. Int. J. Gynecol. Cancer18(4), 803–808 (2008).
   PubMed Web of Science ®Google Scholar
• Sovak MA, Dupont J, Hensley ML et al. Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study. Int. J. Gynecol. Cancer17(1), 197–203 (2007).
   PubMed Web of Science ®Google Scholar
• Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr. Relat. Cancer10(2), 203–208 (2003).
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol.22(14), 2954–2963 (2004).
   PubMed Web of Science ®Google Scholar
• Oza AM, Elit L, Biagi J et al. Molecular correlates associated with a Phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer – NCIC IND 160. J. Clin. Oncol.24(Suppl. 18), 3003 (2006) (Abstract).
   Web of Science ®Google Scholar
• Oza AM, Elit L, Provencher D et al. A Phase II study of temsirolimus (CCI-779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b. J. Clin. Oncol.26(Suppl.), 5516 (2008) (Abstract).
   Google Scholar
• Slomovitz B, Lu KH, Johnston T et al. A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC). J. Clin. Oncol.26(Suppl.), 5502 (2008) (Abstract).
   PubMed Web of Science ®Google Scholar
• Bansal N, Yendluri V, Wenham RM. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control16(1), 8–13 (2009).
   PubMed Web of Science ®Google Scholar
• Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancers. Curr. Cancer Drug Targets6(4), 333–363 (2006).
   PubMed Web of Science ®Google Scholar
• Leslie KK, Laidler L, Albitar L et al. Tyrosine kinase inhibitors in endometrial cancer. Int. J. Gynecol. Cancer15(2), 409–411 (2005).
   Google Scholar
• Oza AM, Eisenhauer EA, Elit L et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J. Clin. Oncol.26(26), 4319–4325 (2008).
   PubMed Web of Science ®Google Scholar
• Wolf J, Slomovitz BM. Novel biologic therapies for the treatment of endometrial cancer. Int. J. Gynecol. Cancer15, 411 (2005).
   Google Scholar
• Wright JD, Powell MA, Rader JS, Mutch DG, Gibb RK. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res.27(5B), 3525–3528 (2007).
   PubMed Web of Science ®Google Scholar
• Nimeiri HS, Oza AM, Morgan RJ et al. Sorafenib (SOR) in patients (pts) with advanced/recurrent uterine carcinoma (UCA) or carcinosarcoma (CS): a Phase II trial of the University of Chicago, PMH, and California Phase II Consortia. J. Clin. Oncol.26(Suppl.), 5585 (2008) (Abstract).
   Google Scholar
• Santin AD, Bellone S, Gokden M et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin. Cancer Res.8(5), 1271–1279 (2002).
   PubMed Web of Science ®Google Scholar
• Slomovitz BM, Broaddus RR, Burke TW et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J. Clin. Oncol.22(15), 3126–3132 (2004).
   PubMed Web of Science ®Google Scholar
• Santin AD, Bellone S, Siegel ER et al. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am. J. Obstet. Gynecol.192(3), 813–818 (2005).
   PubMed Web of Science ®Google Scholar
• Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N. Engl. J. Med.357(1), 39–51 (2007).
   PubMed Web of Science ®Google Scholar
• Fleming GF, Sill MA, Thigpen JT, Adler LM, Berek JS, DiSilverstro PA. Phase II evaluation of trastuzumab in patients with advanced or recurrent endometrial carcinoma: a report on GOG 181B. J. Clin. Oncol.22, 1821 (2003) (Abstract).
   Google Scholar
• Slomovitz BM, Broaddus RR, Schmandt R et al. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol. Oncol.95(1), 32–36 (2004).
   PubMed Web of Science ®Google Scholar
• Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur. J. Cancer38(Suppl. 5), S77–S82 (2002).
   Google Scholar
• Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr. Cancer Drug Targets5(3), 171–193 (2005).
   PubMed Web of Science ®Google Scholar
• Hogberg T, Rosenberg P, Kristensen G et al. A randomized Phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J. Clin. Oncol.250, 5503 (2007) (Abstract).
   Google Scholar